Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases   3 Products   28 Trials   310 News 


«123456789»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment. (Pubmed Central) -  Aug 25, 2021   
    To the best of our knowledge, no publications are available on cases in which a vision loss and the normal visual function can be reverted by intravitreal injection with Conbercept. Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy. (Pubmed Central) -  Aug 20, 2021   
    Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept. Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. (Pubmed Central) -  Aug 11, 2021   
    The corticosteroids approach is mainly based on the employment of triamcinolone acetonide, dexamethasone and fluocinolone acetonide molecules...Furthermore, several new molecules are currently under investigation. Intravitreal drugs focus their activity on a wide range of therapeutic targets and are safe and efficacy in managing retinal diseases.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, faricimab (RG7716) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Review, Journal:  Longer-acting treatments for neovascular age-related macular degeneration-present and future. (Pubmed Central) -  Jul 7, 2021   
    Long-lasting treatments provide promising solutions for this unmet need by achieving better results with less mandatory injections. This review aims to cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial termination:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) (clinicaltrials.gov) -  Jun 22, 2021   
    P3,  N=1157, Terminated, 
    Intravitreal conbercept injection by three monthly loading doses followed by PRN treatment regimen was safe and efficacious for patients with macular oedema secondary to CRVO through 1-year follow-up. Trial completion date: Jan 2022 --> May 2021 | Active, not recruiting --> Terminated; desired primary endpoint was not met
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial termination, Trial primary completion date:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (clinicaltrials.gov) -  Jun 21, 2021   
    P3,  N=1157, Terminated, 
    It is effective and cost-effective to treat DME by utilizing triamcinolone as an adjunct to the combination of anti-VEGF. Trial completion date: Mar 2022 --> May 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Sep 2020; desired primary endpoint was not met
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography. (Pubmed Central) -  May 15, 2021   
    Anti-vascular endothelial growth factor treatment may have a positive effect on macular perfusion status. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    [VIRTUAL] Inhibition of corneal neovascularization with rAAV-anti-VEGF in mouse corneal injury models () -  May 13, 2021 - Abstract #ARVO2021ARVO_3165;    
    This one-way air-fluid exchange procedure can effectively exchange the vitreous hemorrhage and improve visual acuity of PDR patients who develop vitreous rehemorrhage post vitrectomy without obvious complications. Our study demonstrates the potential and relative safety of rAAV-based anti-angiogenesis therapy in the treatment of corneal neovascularization progression.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury. (Pubmed Central) -  May 7, 2021   
    Both Ranibizumab and Conbercept inhibited epiretinal scar formation at the wound site, with Conbercept showing the greatest effect (maximal length of scar (L), L = 503 ± 82.44 μm, L = 355 ± 43.66 μm, and L = 250.33 ± 36.02 μm). Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR).
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT. (Pubmed Central) -  May 5, 2021   
    Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR). The external limiting membrane status and hyperreflective foci >20 at baseline could be good predictors for short-term visual outcome, whereas the central subfield thickness and ellipsoid zone status at baseline and their changes over time may predict visual improvement in patients with retinal vein occlusion macular edema after intravitreal conbercept injection.
  • ||||||||||  RC28-E / Rongchang Pharma
    Enrollment open:  Evaluation of RC28-E Injection in Diabetic Macular Edema (clinicaltrials.gov) -  Apr 27, 2021   
    P2,  N=150, Recruiting, 
    A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. (Pubmed Central) -  Apr 10, 2021   
    Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Rapid progression of high-risk proliferative diabetic retinopathy induced by insulin intensive therapy: A case report. (Pubmed Central) -  Feb 27, 2021   
    Insulin IT for untreated proliferative diabetic retinopathy (PDR) patients can cause severe and irreversible consequences, so for such patients, the conservative treatment for glycemic control may be much safer. But if insulin IT is inevitable, the patient should undergo PRP promptly before the IT, and close eye monitoring during the IT is also essential.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial primary completion date:  Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy (clinicaltrials.gov) -  Feb 25, 2021   
    P=N/A,  N=226, Enrolling by invitation, 
    In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation. Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Retrospective data, Review, Journal:  Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic Retinopathy: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Feb 25, 2021   
    To evaluate the efficacy and safety of intravitreal conbercept (IVC) for diabetic retinopathy (DR) compared with intravitreal triamcinolone acetonide (IVTA)...Patients with IVC treatments acquired better self-care, mobility, social, and mental scores compared with IVTA (P < 0.001). Current evidence shows that IVC has better effects and safety than IVTA in treating DR, and it can significantly enhance the QoL of patients with DR.